Ypsomed and Mediq announced today that they completed the sale of mail-order retailer for diabetes care DiaExpert.
Germany-based DiaExpert specializes in insulin pump therapy. The companies previously announced the sale of DiaExpert in October. This sale allows Ypsomed to focus on the manufacture and sale of its own medical technologies.
That focus continues to narrow after last month’s announcement of the discontinuation of Ypsomed’s agreement with Eli Lilly. Lilly elected to stop their joint collaboration to enter the U.S. insulin pump market.
Burgdorf, Switzerland-based Ypsomed’s technologies include the YpsoPump insulin pump. The company recently announced German authorization for the use of its pump with Abbott and CamDiab’s technologies, forming an automated insulin delivery system.
Ypsomed said it obtained all approvals and fulfilled all conditions for the transaction by the end of 2022. Today’s announcement confirms the legal completion of the deal, leading to a heightened focus on the company’s own products.
“In the area of injection systems and in our insulin pump business, we see enormous growth potential in the coming years. Digitization also offers new business models and opportunities,” said Ypsomed CEO Simon Michel. “We are therefore continuing on our path to becoming a provider of integrated healthcare services.”
